One molecule, ASP0367 (bocidelpar sulfate), is in a Phase 1b clinical trial to assess safety, tolerability, and preliminary efficacy in DMD boys (NCT04184882), and a previous Phase 1 study has been conducted on healthy adults demonstrating that the drug is well-tolerated, rapidly absorbed, and modulates PPARδ target genes [131]. This evidence concerns the gene PPARD and Duchenne muscular dystrophy.